Efficiency of the home intravenous antibiotics treatment in cystic fibrosis;Eficiencia del tratamiento antibiótico intravenoso domiciliario en la fibrosis quística

Medicina Clinica

Volumn 127, Issue 15, 2006, Pages 567-571

  Girón, Rosa María ^a   Cisneros, Carolina ^a   Al Nakeeb, Zaid ^a   Hoyos, Nieves ^a   Martínez, Concha ^a   Ancochea, Julio ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Avoided stay days; Costs saving; Cystic fibrosis; Home intravenous antibiotic treatment

Indexed keywords

ANTIBIOTIC AGENT; CEFTAZIDIME; LINEZOLID; MEROPENEM; TOBRAMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; CYST; DRUG COST; HEALTH CARE COST; HOME CARE; HOSPITALIZATION; HUMAN; LUNG FIBROSIS; TREATMENT PLANNING;

EID: 33751048136     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13093998     Document Type: Article

References (26)

1. Girón RM, Ancochea J. El diagnóstico de la fibrosis quística de adultos. Arch Bronconeumol. 2000;36:3-6.
2. Cystic Fibrosis Foundation. Patient Registry 2002 Annual Report. Bethesda: Cystic Fibrosis Foundation; 2003.
3. Elborn JS, Prescott RJ, Stack BH, Goodchild MC, Bates J, Pantin C, et al. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs. Thorax. 2002;55:355-8.
4. Salcedo A, Girón RM, Beltrán B, Martínez A, Máiz L, Suárez L. Conferencia de Consenso. Tratamiento antibiótico intravenoso domiciliario en la fibrosis quística. Arch Bronconeumol. 2003; 39:469-75.
5. Girón RM, Martínez A, Máiz L, Salcedo A, Beltrán B, Martínez MT, et al. Tratemiento intravenoso domiciliario en las Unidades de Fibrosis Quística de la Comunidad de Madrid. Med Clin (Barc). 2004;122:648-52.
6. Gilbert J, Robinson T, Littlewood JM. Home intravenous antibiotic treatment in cystic fibrosis. Arch Dis Child. 1988;63:512-7.
7. Donati MA, Guenette G, Auerbach H. Prospective controlled study of home and hospital therapy of cystic fibrosis pulmonary disease. J Pediatr. 1987;111:28-33.
8. Kuzemko JA. Home treatment of pulmonary infection in cystic fibrosis. Chest. 1988;94 Suppl:162-5.
9. Bosworth DG, Nielson DW. Effectiveness of home versus hospital care in the routine treatment of cystic fibrosis. Pediatr Pulmonol. 1997;24:42-7.
10. Wolter JM, Bowler SD, Nolan PJ, McCormack JG. Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects. Eur Respir J. 1997;10:896-900.
11. Bramwell EC, Halpin DM, Duncan-Skingle F, Hodson ME, Geddes DM. Home treatment of patients with cystic fibrosis using the «Intermate»: the first year's experience. J Adv Nurs. 1995;22:1063-7.
12. Bosso J, Stephenson S, Herbst J. Feasibility and cost saving of intravenous administration of aminoglycosides in outpatients with cystic fibrosis. Drug Intell Clin Pharm. 1985;19:52-4.
13. Bakker W, Vinks AA, Mouton JW, De Jonge P, Verzijl JG, Heijerman HG. Continuous intravenous home treatment of airway infections using ceftazidime administration via portable pump in patients with cystic fibrosis; a multicenter study. Ned Tijdschr Geneeskd. 1993;137:2486-91.
14. Graf von der Shulenburg J, Greiner W, Klerrke U, Wahn U. Economic aspect in treatment of cystic fibrosis with chronic pulmonary Pseudomonas infection. Ambulatory intravenous therapy in comparision with inpatient treatment. Med Klin. 1997;15:626-9.
15. Kane R, Jennison K, Word C, Black P, Herbst J. Cost saving and economic considerations using home intravenous antibiotic therapy for cystic fibrosis patients. Pediatr Pulmonol. 1988;4:84-9.
16. Krauth C, Busse R, Smaczny C, Ullrich G, Wagner TO, Weber J, et al. Cost comparison of hospital and ambulatory i.v. therapy in adult cystic fibrosis patients. Results of a controlled prospective study. Med Klin. 1999;94:541-8.
17. Bosworth DG, Nielson DW. Effectiveness of home versus hospital care in the routine treatment of cystic fibrosis. Pediatr Pulmonol. 1997;24:42-7.
18. Krauth C, Jalilvand N, Welte T, Busse R. Cystic fibrosis. Cost of illness and considerations for the economic evaluation of potential therapies. Pharmacoeconomics. 2003;21:1001-24.
19. Wilson R, Dowling R. Pseudomonas aeruginosa and other related species. Thorax. 1998;53:213-9.
20. 1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Thorax. 1998;53:732-7.
21. MRSA in cystic fibrosis. Meeting Report. J Hosp Infect. 1998;40:179-91.
22. Givney R, Vickery A, Holliday A, Pegler M, Benn R. Methicillin-resistant Staphylococcus aureus in a cystic fibrosis unit. J Hosp Infect. 1997;35:27-36.
23. Cantón R, Girón R, Martínez-Martínez L, Oliver A, Solé A, Valdezate S, et al. Patógenos multirresistentes en la fibrosis quística. Arch Bronconeumol. 2002;38:376-85.
24. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med. 2003;138:135-42.
25. Ferrin M, Zuckerman JB, Meagher A, Blumberg EA. Successful treatment of methicillin-resistant Staphylococcus aureus pulmonary infection with linezolid in a patient with cystic fibrosis. Pediatr Pulmonol. 2002;33:221-3.
26. Girón R, Ruiz Velasco L, Buendía B. Utilidad del linezolid en la fibrosis quística. Enferm Infecc Microbiol Clin. 2004;22:369-70.